Table 3.
Symptomatic, laboratory, and radiological characteristics of clinical classifications in the COVID-19 patients.
| N | Mild | Common | Severe | Critical | t/χ2 | P | |
| N | 157 | 2 | 110 | 30 | 15 | ||
| Age | 51.49 ± 17.39 | 26.00 ± 1.41 | 46.60 ± 15.56 | 62.70 ± 15.82 | 68.27 ± 10.85 | 17.217 | .000 |
| Gender | 5.724 | .017 | |||||
| Male | 81 (51.6%) | 0 (0.0%) | 53 (48.2%) | 16 (53.3%) | 12 (80.0%) | ||
| Female | 76 (48.4%) | 2 (100.0%) | 57 (51.8%) | 14 (46.7%) | 3 (20.0%) | ||
| Signs and symptoms | |||||||
| Fever | 118 (75.2%) | 1 (50.0%) | 76 (69.1%) | 26 (86.7%) | 15 (100.0%) | 9.814 | .002 |
| Cough | 94 (59.9%) | 0 (0.0%) | 68 (61.8%) | 17 (56.7%) | 9 (60.0%) | 0.004 | .947 |
| Fatigue | 39 (24.8%) | 0 (0.0%) | 24 (21.8%) | 9 (30.0%) | 6 (40.0%) | 3.277 | .070 |
| Chest tightness&dyspnea | 28 (17.8%) | 0 (0.0%) | 11 (10.0%) | 10 (33.3%) | 7 (46.7%) | 17.918 | .000 |
| Sore throat | 13 (8.3%) | 0 (0.0%) | 10 (9.1%) | 3 (10.0%) | 0 (0.0%) | 0.602 | .438 |
| Headache | 6 (3.8%) | 0 (0.0%) | 6 (5.5%) | 0 (0.0%) | 0 (0.0%) | 1.882 | .170 |
| Muscle soreness | 22 (14.0%) | 0 (0.0%) | 14 (12.7%) | 8 (26.7%) | 0 (0.0%) | 0.002 | .965 |
| Nausea or vomiting | 7 (4.5%) | 0 (0.0%) | 5 (4.5%) | 1 (3.3%) | 1 (6.7%) | 0.057 | .812 |
| Diarrhea | 16 (10.2%) | 0 (0.0%) | 15 (13.6%) | 1 (3.3%) | 0 (0.0%) | 3.710 | .054 |
| Anorexia | 28 (17.8%) | 0 (0.0%) | 19 (17.3%) | 6 (20.0%) | 3 (20.0%) | 0.264 | .608 |
| SpO2 | 92.5 ± 15.0 | 98.5 ± 0.70 | 96.7 ± 2.4 | 92.4 ± 6.0 | 60.7 ± 33.8 | 49.588 | .000 |
| CT | 17.958 | .000 | |||||
| Ground-glass opacity | 30 (19.4) | 0 (0.0%) | 26 (23.6%) | 2 (6.7%) | 2 (13.3%) | ||
| Local patchy shadowing | 15 (9.7%) | 0 (0.0%) | 15 (13.6%) | 0 (0.0%) | 0 (0.0%) | ||
| Bilateral patchy shadowing | 92 (59.4%) | 0 (0.0%) | 65 (59.1%) | 22 (73.3%) | 5 (33.3%) | ||
| consolidation | 18 (11.6%) | 0 (0.0%) | 4 (3.6%) | 6 (20.0%) | 8 (53.3%) | ||
| Routine blood test | |||||||
| White-cell count, E+09/L | 33.555 | .000 | |||||
| ≥10 | 19 (12.1%) | 0 (0.0%) | 4 (3.6%) | 4 (13.3%) | 11 (73.3%) | ||
| ≥4, <10 | 125 (79.6%) | 2 (100.0%) | 93 (84.5%) | 26 (86.7%) | 4 (26.7%) | ||
| <4 | 13 (8.3%) | 0 (0.0%) | 13 (11.8%) | 0 (0.0%) | 0 (0.0%) | ||
| Lymphocyte count, E+09/L | 12.133 | .000 | |||||
| ≥4 | 2 (1.3%) | 0 (0.0%) | 1 (0.9%) | 1 (3.3%) | 0 (0.0%) | ||
| ≥0.8, <4 | 97 (61.8%) | 1 (50.0%) | 78 (70.9%) | 14 (46.7%) | 4 (26.7%) | ||
| <0.8 | 58 (36.9%) | 1 (50.0%) | 31 (28.2%) | 15 (50.0%) | 11 (73.3%) | ||
| Platelet count, E+09/L | 0.191 | .662 | |||||
| ≥300 | 4 (2.5%) | 0 (0.0%) | 4 (3.6%) | 0 (0.0%) | 0 (0.0%) | ||
| ≥100, <300 | 112 (71.3%) | 1 (50.0%) | 81 (73.6%) | 21 (70.0%) | 9 (60.0%) | ||
| <100 | 41 (26.1%) | 1 (50.0%) | 25 (22.7%) | 9 (30.0%) | 6 (40.0%) | ||
| Hematocrit | 4.644 | .031 | |||||
| <40 (male), <35 (female) | 98 (62.4%) | 0 (0.0%) | 64 (58.2%) | 23 (76.7%) | 11 (73.3%) | ||
| 40–50 (male), 35–45 (female) | 59 (37.6%) | 2 (100.0%) | 46 (41.8%) | 7 (23.3%) | 4 (26.7%) | ||
| C-reactive protein (mg/L) | 15.280 | .000 | |||||
| >8 | 111 (70.7%) | 0 (0.0%) | 70 (63.6%) | 26 (86.7%) | 15 (100.0%) | ||
| ≤8 | 46 (29.3%) | 2 (100.0%) | 40 (36.4%) | 4 (13.3%) | 0 (0.0%) | ||
| D-dimer (mg/L) | 26.665 | .000 | |||||
| >0.55 | 104 (66.2%) | 0 (0.0%) | 60 (54.5%) | 29 (96.7%) | 15 (100.0%) | ||
| ≤0.55 | 53 (22.8%) | 2 (100.0%) | 50 (45.5%) | 1 (3.3%) | 0 (0.0%) | ||